[{"id":"94fc6139-3248-47b5-b7ab-1c8fcba69d09","acronym":"KEYNOTE-F86","url":"https://clinicaltrials.gov/study/NCT05787587","created_at":"2023-03-28T14:05:08.346Z","updated_at":"2025-02-25T16:18:41.344Z","phase":"Phase 1","brief_title":"A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors","source_id_and_acronym":"NCT05787587 - KEYNOTE-F86","lead_sponsor":"IDEAYA Biosciences","biomarkers":" HRD","pipe":" | ","alterations":" HRD","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • IDE161"],"overall_status":"Recruiting","enrollment":" Enrollment 216","initiation":"Initiation: 04/05/2023","start_date":" 04/05/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-10-28"}]